Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.66 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.66 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13693055 | 0.92 | ITGB1 (0.54) | ITGB1ITGA4ITGB7OPRK1OPRM1 | |
| SCHEMBL13689656 | 0.88 | ITGB1 (0.55) | ITGB1ITGA4ITGB7OPRK1OPRM1 | |
| SCHEMBL13601993 | 0.82 | ITGB1 (0.84) | ITGB1ITGA4ITGB7 | |
| SCHEMBL8278642 | 0.81 | ITGA4 (0.79) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13602006 | 0.81 | ITGB1 (0.79) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13602017 | 0.81 | ITGB1 (0.82) | ITGB1ITGA4ITGB7 | |
| SCHEMBL13693097 | 0.80 | ITGB1 (0.46) | ITGB1ITGA4ITGB7OPRK1OPRM1 | |
| SCHEMBL13602106 | 0.80 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6807415 | 0.80 | ITGA4 (0.50) | ITGB1ITGA4ITGB7OPRK1OPRM1 | |
| SCHEMBL6807468 | 0.78 | ITGB1 (0.54) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | ITGB1 7/4885ITGA4 4/4885ITGB7 46/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | ITGB1 8/4885ITGA4 25/4885ITGB7 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.